Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.01.05.20249027: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The current study was approved by the Research Ethics Committee of Hospital Clínico Universitario INCLIVA (March 2020). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Patients and specimens: A total of 58 non-consecutive patients (38 males and 20 females; median age, 62.5 years; range, 27 to 82 years) were recruited at the COVID-19 follow-up unit of Hospital Clínico Universitario of Valencia, at a median of 85 days (range, 58 to 191 days) after onset of COVID-19 symptoms. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources SARS-CoV-2 RBD IgG … SciScore for 10.1101/2021.01.05.20249027: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The current study was approved by the Research Ethics Committee of Hospital Clínico Universitario INCLIVA (March 2020). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Patients and specimens: A total of 58 non-consecutive patients (38 males and 20 females; median age, 62.5 years; range, 27 to 82 years) were recruited at the COVID-19 follow-up unit of Hospital Clínico Universitario of Valencia, at a median of 85 days (range, 58 to 191 days) after onset of COVID-19 symptoms. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources SARS-CoV-2 RBD IgG immunoassay: IgG antibodies binding to SARS-CoV-2 RBD made in Sf9 cells infected with recombinant baculoviruses (Invitrogen, CA, USA) were measured by an enzyme-linked immunosorbent assay (ELISA) as previously described [23]. Sf9suggested: CLS Cat# 604328/p700_Sf9, RRID:CVCL_0549)Software and Algorithms Sentences Resources The analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The current study has several limitations that must be acknowledged; predominantly, the reduced cohort size. Second, T-cell immunity analyses were conducted at a single time point. We cannot rule out that detectability of the two SARS-CoV-2-reactive T cells by the immunoassay used herein may fluctuate over time. Moreover, no whole blood specimens drawn at the time of patient hospitalization were available for T-cell immunity assessment. Third, T cells and antibodies targeting other antigen specificities, which may afford protection against SARS-CoV-2, were not evaluated. Fourth, T-cell functionalities other than IFN-γ production upon antigenic stimulation were not explored. Fifth, we cannot be certain whether our whole blood T-cell immunoassay might be less sensitive than others using fresh or cryopreserved isolated PBMCs. Sixth, taking serum peak levels of IL-6, Dimer-D and ferritin during the first 15 days after symptoms onset is an admittedly arbitrary time point for analyses which may not have captured the true net state of systemic inflammation generated shortly after SARS-CoV-2 infection. In summary, we have shown that a relatively low number of subjects who developed severe forms of COVID-19 had detectable SARS-CoV-2-S1/M IFNγ CD4+ and CD8+ T cells at medium term after clinical diagnosis (up to 6 months), particularly those with concurrent comorbidities. Our data also indicated that serum levels of RBD-specific IgGs decline over time, becoming undetectable in some pati...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
